Aleniglipron pill delivers 12% weight loss in 36 weeks

An experimental once-daily GLP-1 pill helped adults with obesity or overweight lose up to 12.1% of their body weight in 36 weeks, according to early-stage trial results published in the journal Science. The drug, called aleniglipron, targets the same gut hormone pathway as injectable medicines like Wegovy and Zepbound, but comes in a small tablet you can swallow with or without food, raising hopes for a more convenient alternative to injections that dominate the $20-billion-plus obesity market.

The findings mark a step toward oral versions of a class of drugs that have transformed weight-loss treatment since Novo Nordisk’s semaglutide injection (Wegovy) was approved in 2021. Those shots mimic GLP-1, a hormone that curbs appetite and slows digestion, but require refrigeration, sterile pens, and clinic visits. Aleniglipron, developed by Novo Nordisk, is a non-peptide small molecule that binds the same receptor but is stable at room temperature and can be mass-produced using standard tablet-making equipment, potentially lowering cost and logistical hurdles.

In a mid-stage study of 199 adults with obesity (average BMI 37), those given the highest dose of aleniglipron lost an average 9.4% of body weight, while the placebo group lost 2.2%. About 70% of participants on the highest dose dropped at least 5% of body weight, the threshold regulators consider clinically meaningful. Mild to moderate nausea was the most common side effect, affecting roughly a third of users, but most cases resolved within weeks. The trial ran for nine months, so longer-term safety and durability data are still needed.

If larger trials confirm these results, aleniglipron could reach the market within three to five years, giving patients a daily pill as an alternative to weekly injections. Oral GLP-1 drugs could expand access in lower-income countries and among patients who fear needles. Analysts also expect oral versions to undercut the price of injectables, which currently cost up to $1,000 per month in the U.S. without insurance. For now, Novo Nordisk plans a phase 3 program starting later this year, with regulatory filings possible by 2027.